Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company developing therapies for neurological and psychiatric disorders. The company’s lead candidate, Azetukalner, is a Kv7 potassium channel opener in Phase 3 development for epilepsy, including focal onset seizures and primary generalized tonic-clonic seizures, as well as for neuropsychiatric conditions such as major depressive disorder and bipolar depression. Xenon also has early-stage programs including XEN1701, a sodium channel candidate for pain, and XEN1120, a Kv7 potassium channel candidate for pain. In addition, the company works with Neurocrine Biosciences under a license and collaboration agreement on NBI-921355, a Nav1.2/1.6 sodium channel inhibitor being studied in Phase 1 trials for certain epilepsies. Incorporated in 1996, Xenon is headquartered in Burnaby, Canada, and its common shares trade on NASDAQ under the symbol XENE.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XENE
|
$42.29
|
8.2% Upside
|
Fair
|
$74.87
|
91.5% Upside
|
Bargain
|
Weak
|
0.0%
|
November 11, 2026
|
3.0x
|
3.785 B
|
2.547 B
|
0.2%
|
93.9%
|
26.3
|
82.7%
|
